A monoclonal antibody for Alzheimer’s disease; FDA/European status varies by region.
A body of studies is showing that a blood marker called p-tau217 can forecast an elevated risk of cognitive impairment in healthy older adults years before symptoms appear. The evidence is not yet clinical-ready, but it is guiding trials that aim to slow or prevent Alzheimer’s disease and is being tested in Scotland’s primary care setting.
The UK trial is testing Trontinemab in 55–80-year-olds with high p-tau217 levels to see if dementia can be delayed or prevented. About 1,600 participants globally will be recruited over four to six years, with initial screening beginning this week at the Surrey and Borders Partnership NHS Foundation Trust.